rFC: The New Compendial Standard
The implementation of rFC-based methods (Ph. Eur. 2.6.32 and USP <86>) follows a rigorous, science-led path designed to ensure sensitivity and reproducibility while eliminating the variability of animal-derived reagents.
At CellMade, we guide you through a three-phased implementation strategy that ensures your method is robust, compliant, and ready for routine QC.
Phase I: Preliminary Testing & Matrix Screening
The objective of Phase I is to establish the Maximum Valid Dilution (MVD) and identify any inhibition or enhancement factors inherent in your product matrix.
- Positive Product Control (PPC): We test the product at varying dilutions with a known endotoxin spike.
- Target Recovery: Following compendial requirements, we identify the specific dilution where PPC recovery falls strictly within the 50–200% range.
- Interference Identification: Early detection of matrix interference allows us to determine if standard dilution is sufficient or if advanced pre-treatment is required in Phase II.
Phase II: Method Optimization & Troubleshooting
For "difficult" matrices—such as high-protein biologics or viscous formulations—standard dilution may not be enough to neutralize interference.
- Sample Pre-treatment: We develop custom protocols involving pH adjustment, specialized dispersing agents, or cation-chelating buffers to resolve inhibition.
- The EndoLISA® Solution: For samples that remain recalcitrant to standard rFC assays, we utilize the EndoLISA® platform. This solid-phase assay effectively "washes away" interfering matrix components while binding the endotoxin, serving as a powerful problem-solving tool for OOS investigations and complex products.
Phase III: Global Product-Specific Validation (Compendial Alignment)
As of 2025, the regulatory landscape has been harmonized, significantly reducing the validation burden for manufacturers.
- European Pharmacopoeia (Ph. Eur. 2.6.32): Since rFC is a standalone compendial chapter, a full de novo validation is unnecessary. We perform Product-Specific Verification, demonstrating the method's suitability across three independent production batches.
- USP/FDA (USP <86>): Significant Update: As of May 2025, USP <86> has officially made rFC a compendial method. The requirement to demonstrate equivalency to LAL (per USP <1223>) has been removed for new products.
- Streamlined Path: In both jurisdictions, a successful Inhibition/Enhancement (I/E) screening is now the primary requirement to prove the method’s fitness for purpose, allowing for faster transition and reduced time-to-market.
